Head-to-head evidence
Motixafortide vs Plerixafor
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CXCR4 · full Multiple Myeloma pipeline
Motixafortide
Marketed by Ayrmid Ltd. and partners
NCT02639559 · Phase 2 · completed
The study was non-randomized, open-label, and had no comparator arm, with 50 participants overall and 24 evaluable donors for the primary endpoint. Although 22 of 24 donors met the mobilization target, this uncontrolled design cannot establish how motixafortide compares with another mobilization strategy; the primary endpoint was a CD34+ cell mobilization measure rather than a direct clinical outcome.
Next expected readout: December 2026 · NCT07101445 (registry estimate)
Plerixafor
Marketed by Sanofi
NCT00103662 · Phase 3 · completed
This was a randomized, quadruple-blinded, placebo-controlled Phase 3 trial with a reasonably large sample (302 patients) and a clinically meaningful primary endpoint (achieving a target stem cell yield within a defined apheresis window). Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: December 2027 · NCT07188090 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Motixafortide's landscape · Plerixafor's landscape